Abstract. Vascular cell adhesion molecule 1 (VCAM-1), a member of the Ig superfamily originally identified on activated endothelium, binds to the integrin very late antigen-4 (VLA-4), also known as ot4~l or CD49d/CD29, to support cell-cell adhesion. Studies based on cell adhesion to two alternatively spliced forms of VCAM-1 or to chimeric molecules generated from them and intercellular adhesion molecule-1 (ICAM-1) have demonstrated two VLA-4 binding sites on the predominate form of VCAM-1. Here, we studied VLA-4-dependent adhesion of the lymphoid tumor cell line Ramos to cells expressing wild type and mutant forms of VCAM-1. Results based on domain deletion mutants demonstrated the existence and independence of two VLA-4-binding sites located in the first and fourth domains of VCAM-1. Results based on amino acid substitution mutants demonstrated that residues within a linear sequence of six amino acids found in both domain 1 and 4 were required for VLA-4 binding to either domain. Five of these amino acids represent a conserved motif also found in ICAM domains. We propose that integrin binding to these Ig-like domains depends on residues within this conserved motif. Specificity of integrin binding to Ig-like domains may be regulated by a set of nonconserved residues distinct from the conserved motif.
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T
H~ binding of vascular cell adhesion molecule 1 (VCAM-1) L to very late antigen-4 (VLA-4) (a4#t) has been implicated in numerous physiologic and pathophysiologic processes involving cell-cell adhesion (51) . On activated endothelium, VCAM-1 supports the adhesion of lymphocytes (7, 15, 36, 42, 47) , monocytes (6) , eosinophils (4, 14, 62) , basophils (4) , natural killer cells (1) , and certain tumor cells, particularly malignant melanoma and osteosarcoma (19, 27, 51, 56) . Adhesion of VLA-4-expressing cells to endothelium has been implicated in the pathogenesis of many diseases and disease processes, including rheumatoid arthritis (24, 30, 40, 57) , osteoarthritis (24, 30) , allogeneic graft rejection (5, 38) , graft-versus-host disease (33) (34) (35) , encephalomyelitis (2, 65) , delayed-type hypersensitivity reactions (32) , tumor metastasis (19, 27, 41, 56) , and atherogenesis (9) . VCAM-1 has also been identified on a variety of nonvascular cell types, including follicular dendritic cells (17, 26) , bone marrow stromal cells (29, 45, 48) , secondary myoblasts (44) , some macrophages (43) , certain renal epithelial cells (43) , fibroblast-like synoviocytes (28, 30) , reac- tive mesothelial cells (23, 43) , stimulated astrocytes (22) , and stimulated cortical neurons (3) . Roles for VCAM-1 in germinal center development (17) , lymphopoiesis (29, 45, 48) , and myogenesis (44) have been suggested.
Alternative splicing of mRNA from a single VCAM-1 gene can produce two forms of VCAM-1 (8, 21, 39) : a form containing seven Ig-like domains (VCAM-7D) and a form containing six Ig-like domains (VCAM-6D). The two forms of VCAM-1 are identical in amino acid sequence except for the absence in VCAM-6D of domain 4 (8, 21, 36, 39) . Both forms of VCAM-1 have been isolated as eDNA from libraries prepared from stimulated endothelial cells, and as expressed in transfected cell lines, both support VLA-4-dependent adhesion (21, 59) . mRNA for both VCAM-6D and VCAM-7D has been identified in cultured endothelial cells (8, 21, 28) , synovial fibroblasts (28) , and mesothelial cells (23) , although VCAM-7D mRNA predominates particularly in chronically stimulated cells. At the protein level, only VCAM-7D has been identified on endothelial cells and synovial fibroblasts stimulated for 24 h with TNF (8, 28) ; however, after 2 h of stimulation of synovial fibroblasts, a glycoprotein with an apparent molecular weight 10-15 kD less than VCAM-7D has been clearly identified (28) . In the mouse, a three-domain, glyeophosphatidylinositol-anchored form of VCAM-1 has been identified in addition to VCAM-7D (66; and Kinashi, T., Y. St. Pierre, C.-H. Huang, and T. A. Springer, manuscript submitted for publication).
Recent studies suggest that VLA-4 binds to VCAM-1 via two distinct sites. Based on the ability of anti-VCAM-1 mAb to inhibit lymphocyte adhesion to VCAM-TD versus VCAM-6D transfectants, we have concluded that one VLA-4 binding site is shared between VCAM-7D and VCAM-6D, whereas a second binding site localizes to the alternatively spliced domain 4 (59) . The high degree of sequence homology between domain 1 and domain 4 suggested that the shared VLA-4 binding site localizes to domain 1. Based on lymphoid cell adhesion to chimeric constructs generated from VCAM-7D or VCAM-6D and intercellular adhesion molecule-I (ICAM-1), Osborn et al. (37) has concluded that VLA-4 binds distinctly to domains 1 and 4.
Here we have characterized VLA-4 binding sites in VCAM-1 based on domain deletion and amino acid substitution mutants, similar to the strategy previously used to identify binding sites in ICAM-1 for its integrin receptors LFA-I (52) and Mac-1 (13) . In a first series of experiments, domain 1 deletion mutants of both VCAM-7D and VCAM-6D were analyzed for expression and lymphoid cell binding, and compared to wild-type forms. The domain specificities of several anti-VCAM-1 mAb were determined and compared to the ability of the mAb to inhibit cell binding. In a second series of experiments, amino acid substitution mutations were targeted to domains 1 and 4, and analyzed for binding to VLA-4-expressing cells. Our results not only demonstrate independent VLA-4 binding sites in domain 1 and domain 4 of VCAM-7D, but also demonstrate a critical binding function for residues within a six-amino acid sequence found in domain 1 and domain 4. Five of these represent a conserved motif also found in ICAM domains.
Materials and Methods

Cell Culture
The VLA-4-expressing human B lymphoblastoid cell line Ramos and SV-40 transformed African green monkey kidney cells (COS) were maintained in RPMI 1640 with 10% FCS, 5 mM glutamine, and 50 izg/ml gentamicin. Human umbilical vein endothelial cells (HUVEC) were maintained as previously described (59) .
Antibodies
The mouse anti-VCAM-1 mAbs HAE-2a, HAE-2b, HAE-2c, HAE-2d, HAE-2j, and HAE-2f were generated following immunization of female BALB/c mice with HUVEC stimulated for 6 h with TNF, according to previously described methods (50) . Hybridomas were screened by testing tissue culture supernatant for reactivity with purified VCAM-7D. Other mouse anti-VCAM-1 mAb used were 1.4C3 (63) and 4B9 (7) . All mAb used were isotype IgG1. mAb were used as neat tissue culture supernatant (HAE-2b, HAE-2c, HAE-2d, HAE-2j, and HAE-2f), as a 1:500 dilution of ascites (HAE-2a), or as 20 ~tg/ml of purified protein (1.4C3 and 4B9). The mouse anti-human VLA-4 mAb HP2/1 (46) was used as 40 ~tg/ml of purified protein (AMAC Corp., Westbrook, ME).
Generation of VCAM-1 Mutants
Ollgonucleotide-directed mutagenesis was used to generate VCAM-I domain deletion and amino acid substitution mutants, according to methods previously described (52) . Domain deletion mutations were made using single strand templates containing the VCAM 7D cDNA clone 1Ell or the VCAM-6D cDNA clone 41 in the expression vector CDM8. Domain deletions were guided by previous assignment of VCAM-1 domain boundaries (36) . Amino acid substitution mutants were made using single strand templates of VCAM-6D or VCAM 7D/DI-, a domain 1 deletion mutant of W.AM-7D. Following second-strand synthesis and transformation in Escherichia coil, mutants were isolated by screening for unique restriction sites conferred by mutant oligonucleotides. DNA sequencing confirmed each mutation.
Generation of a VCAM-I Domain 4~Human IgG Chimeric Molecule
A chimera containing VCAM-1 domain 4 fused to human IgGt hinge, CH2, and CH3 was generated according to methods previously described (55) . Using W.AM-7D cDNA and the ollgonucleotide primers 5°TTTACT -GTTGAGATCTCCCCT and 5'TTTCTCGAGTCTCACCTGAGTAGAU~T-CCACCTGGAT, a polymerase chain reaction product containing domain 4 sequence was generated, digested with restriction enzymes HindIII and XhoI, and then ligeted to the expression vector pCDGI (55) . This construct, pCDVC-D4/IgG, was transfected into COS cells, and a soluble chimera containing a dimer of VCAM-1 domain 4 fined to hinge, CH2, and CH3 of IgG1 (VC-D4/IgG) was purified from tissue culture supernatant by protein A-Sepharose chromatography.
Transfected COS Celi Adhesion Assay
COS cells were transfected with purified plnsmid and prepared for assay three days later, as previously described (59) . Transfected COS cells were washed three times with 1% FBS/RPMI at 25°C, and in some cases, preincubated for 15 min with anti-W.AM-1 mAb. Ramos cells were labeled as described (59) with the carboxyltuorescein compound BCECF-AM (Bioprobes, Eugene, OR), resuspended in 1% FBS/RPMI, and in soma cases, preincubated with the anti-VLA-4 mAb HP2/I for 15 rain at 25°C. Ramos cells were added to 60 m m × 15 mm tissue culture dishes (4 × 106/dish) for 10 min at 25°C. Nonadherem cells were removed by five washes using 1% FBS/RPMI, and dishes were fixed with 2% paraformaldehyde in PBS. 
and COS-expressing VCAM-tD(B) or VCAM-7D/DI-(C).
For each experiment, bound Ramos cells were quantified using a fluorescence microscope to score the number of ceils in three to five 100× fields. Phase contrast was used to count the number of COS cells in the same fields. COS ceil transfectants were also labeled with a panel of anti-VCAM-1 mAb for flow cytometry as described (12) 
Results
Generation and Expression of Domain 1 Deletion VCAM-1 Mutants
The amino-terminal Ig-like domains (D]) of VCAM-6D and VCAM-7D (Fig. 1) were deleted using oligunucleotidedirected mutagenesis. Expression of each mutant and wildtype form in COS cells was determined using eight anti-VCAM-1 mAb. Two mAb, 1.4C3 and HAE-2f, recognized each of the wild-type and domain 1 deletion mutants. Four anti-VCAM-1 mAb (HAE-2a, HAE-2b, HAE-2c, and 4B9) recognized VCAM-7D and VCAM-6D transfecrants with a mean linear fluorescence comparable to that of mAb 1.4C3 and HAE-2f (Table I A) . None of these mAb recognized VCAM-6D/D1-or VCAM-7D/D1-transfectants, and therefore represent a group of anti-VCAM-I mAb whose epitopes depend on domain 1.
Two other anti-VCAM-1 mAb (HAE-2d and HAE-2j) recognized VCAM-7D and VCAM-7D/D1-transfectants, but failed to bind (HAE-2d) or weakly bound (HAE-2j) VCAM-6D transfectants (Table I A) . Neither HAE-2d or HAE-2j recognized VCAM-6D/D1-transfectants, and thus these mAb represent a group of mAb whose epitopes depend primarily on domain 4.
Anti-VCAM-1 mAb Reactivity for the Chimera VC-D41IgG
Based on ELISA, three of eight anti-VCAM-1 mAb (HAE2b, HAE-2d, and HAE-2j) were found to react with VC-D4/IgG, a chimeric protein consisting of VCAM-1 domain 4 fused to hinge and constant regions of human IgG (Fig. 2) . Binding is shown as absorbance based on ELISA from a representative of three experiments. Error bars represent 1 SD for duplicate results.
tants (Table I A 
VLA-4-dependent Adhesion to Domain 1 Deletion Mutants
To Seven anti-VCAM-1 mAb were examined for their abilities to inhibit Ramos cell binding to VCAM-7D, VCAM-6D, or VCAM-7D/D1-COS cell transfectants (Fig. 4) . The four domain 1-dependent mAb completely blocked Ramos cell binding to both VCAM-7D and VCAM-6D, whereas none of mAb bound well to COS cells expressing VCAM-7D/D1- (Table I A) , and consequently, none inhibited Ramos cell binding to VCAM-7D/D1-. Two domain 4-dependent rnAb blocked Ramos cell binding to VCAM-TD/D1-but did not block binding to VCAM-7D or VCAM-6D. mAb 1.4C3, whose epitope was independent of both domains 1 and 4, failed to inhibit binding to VCAM-7D, VCAM-6D, or VCAM-7D/DI-, The anti-VCAM-1 mAb HAE-2f was not tested. As a control, the anti-VLA-4 mAb HP2/1 was shown to block Ramos cell binding to any VCAM-l-expressing transfectant. The domain specificity and function-blocking patterns of these mAb provide further evidence for independent VLA-4 binding sites in domain 1 and domain 4 of VCAM-1.
Generation of VCAM-1 Amino Acid Substitution Mutants
VLA-4 binding sites were further characterized based on amino acid substitution mutants of VCAM-6D and VCAM-7D/D1-generated by oligonucleotide-directed mutagenesis. Based on the functional as well as predicted structural similarities between domain 1 of ICAM-1 and domains 1 and 4 of VCAM-1, we targeted for substitution several amino acids in VCAM-1 analogous to amino acids in ICAM4 found to be critical for binding to LFA-1 ( Fig. 5; see reference 52 ). Domain 1 mutations were made in VCAM-6D, and domain 4 mutations were made in VCAM-7D/D1-. Additional mutations were made in domain 1 of VCAM-6D in a region of four amino acids (W-R-T-Q) that lacks a structural analog in ICAM-1 (Fig. 5) . Notation for the mutations uses the oneletter code for the wild-type sequence followed by a slash and the one-letter code for the corresponding mutant sequence; the position of the first amino acid is indicated relative to the predicted NH2-terminal phenylalanine residue of VCAM-7D.
Expression and VI~-4-dependent Adhesion to Domain 1 Amino Acid Substitution Mutants
Seven substitution mutants of one to two amino acids were made in domain 1 of VCAM-6D. Expression of each mutant in COS cells was comparable to that of the wild-type VCAM-6D, as determined by flow cytometry using two mAb, 1.4C3 and HAE-2f, for which the epitopes did not depend on domains 1 or 4 ( Table I B (Table I B) .
Three domain 1 mutants-Q38/S, D40/A, and IM3N/ AD-failed to support Ramos cell adhesion despite good expression and intact conformation of domain 1 (Fig. 6 A) . Binding to four other domain 1 mutants-E29/A, R36/G, E76/A, and R78K/QA-was comparable to that observed to wild-type VCAM-6D.
Expression and VLA-4-dependent Adhesion to Domain 4 Amino Acid Substitution Mutants
Substitution mutants analogous to four of those generated in domain 1 of VCAM-6D were made in domain 4 of VCAM-7D/D1-. Expression after transfection was shown using four anti-VCAM-1 mAb that recognized VCAM-7D/DI-, and conformational integrity was confirmed by the binding of two mAb whose epitopes depended primarily on domain 4 (Table I C). None of these mutants were recognized by mAb whose epitopes depended on domain 1.
Ramos cells failed to bind to the mutants D328/A and L331/A (Fig. 6 B) but did bind to mutants E317/A and K366K/QA as well as they did to VCAM-7D/D1-. Thus, amino acids homologous to those found to be critical in the binding of domain 1 to VLA-4 were also found to be critical in the binding of domain 4 to VLA-4.
Discussion
The binding of the integrin VLA-4 (c~4/31) to VCAM-1, a member of the Ig superfamily with two alternatively spliced forms, plays an important role in mediating chronic inflammarion and numerous other physiologic processes involving cell-cell adhesion. In the present study, we examined cell adhesion to mutant forms of VCAM-1 in order to determine the molecular basis of VLA-4 binding to VCAM4. Our findings not only demonstrate two independent VLA-4 binding sites in domains 1 and 4 but also identify a critical binding function for amino acids within the linear sequence Q-I-D-S-P-L, which is identically expressed in the two domains.
Consistent with previous observations (37, 59) , the exis- The first domain of human ICAM-1 conservatively expresses the five COOH-terminal amino acids of this linear sequence; namely, I33-E34-T35-P36-L37 (Fig. 7) . Furthermore, mutation of E~ of ICAM-1, which is homologous to D4o of domain 1 of VCAM-1 and to D32a of domain 4 ( Fig. 7) , eliminates binding of ICAM-1 to its integrin receptor LFA-1 (52) . In addition, human ICAM-2 and ICAM-3, which also bind integrins (11, 53) , express five amino acid motifs homologous to the VCAM-1 and ICAM-1 motif except for a serine residue substituted for proline at the fourth position. Murine ICAM-1, ICAM-2, and VCAM-1 express a motif homologous to the human VCAM-1 and ICAM-1 motif except for one or two other nonconserved substitutions (Fig.  7) . For each human and murine Ig domain noted in Fig. 7 , the motif is predicted to be found on the turn between/~ sheets C and D.
Based on these functional and predicted structural similarities of VCAM-1 and ICAM domains, we propose that residues with the conserved motif I(L)-D(E)-S(T)-P(or S)-L are necessary but insufficient for integrin binding. A set of nonconserved amino acids may primarily regulate integrin specificity for these Ig-like domains. In the case of ICAM-1, several residues distinct from the conserved I(L)-D(E)-S(T)-P(or S)-L motif are important for LFA-1 binding (52), but no residues in VCAM-1 analogous to these in ICAM-1 were Figure 7 . Alignment of residues from human ICAM-1, ICAM-2, ICAM-3, and VCAM-1 and murine ICAM-1, ICAMo2, and VCAMq (8, 10, 16, 20, 21, 36, 39, 49, 53, 54, 58, 64) . A conserved amino acid motif is boxed. Residues within this motif are proposed to be involved in the binding of these domains to integrins.
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found to be important for VLA-4 binding. Similarly, the residue Q3s in domain 1 of VCAM-1 was required for VLA-4 binding, but a residue analogous to Q3s is not expressed in ICAM-1 (Fig. 5) . Most likely there are other nonconserved residues of VCAM-1 that confer specificity for binding to VLA-4.
There is good precedence for conserved amino acid motifs dictating integrin binding. The motif R-G-D has long been recognized as contributing to integrin binding, particularly to extraceUular matrix proteins such as fibronectin (51) . It is not clear how the domain 1-dependent mAb tested here blocked VLA-4--dependent adhesion to domain 4 as expressed on VCAM-7D, although this phenomenon is clearly not the case for all domain 1-dependent mAb that have been examined (37) . It has been suggested (37) that certain mAb bind to domain 1 on VCAM-7D in such a configuration as to hinder domain 4 activity sterically, or, that upon binding of these mAb, the conformation of domain 4 is perturbed, rendering it incapable of interacting with VLA-4. Another explanation would be that these mAb have a high affinity for a domain 1 epitope and a low affinity for a domain 4 epitope. The 73% amino acid identity between domains 1 and 4 favors cross-reactions between them. High-affinity binding of one Fab of anti-VCAM-1 IgG to domain 1 would greatly increase the local concentration of the other Fab, favoring its binding to domain 4, thus inhibiting domain 4 binding to VLA-4. In the absence of domain 1 expression, the affinity for domain 4 would ordinarily be too low for mAb binding to be detected by flow cytometry. The use of Fab fragments of these domain 1-dependent mAb could help elucidate these possibilities. In the present study, one mAb, HAE-2b, did not bind to VCAM-7D/D1-, which contained one copy of domain 4, but did bind to VC-D4/IgG, which contained two copies, perhaps because bivalent binding of HAE-2b was facilitated. It is also possible that HAE-2b binds VC-D4/IgG and not VCAM-TD/D1-because domains 2 and 3 on VCAM-7D/D1-mask its epitope in domain 4.
In summary, we have demonstrated that VLA-4 binds independently to domains 1 and 4 of VCAM-1, involving amino acids within the linear sequence Q-I-D-S-P-L that is identically expressed in each domain. Five of these amino acids represent the conserved motif I(L)-D(E)-S(T)-P(or S)-L, also found in human ICAM domains. We propose that this conserved motif provides a necessary but insufficient contribution to each VLA-4-binding site and that additional nonconserved residues confer specificity for integrin binding.
